Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Florbetaben is a fluorine-18-labeled stilbene derivative used as a radiopharmaceutical diagnostic agent for positron emission tomography (PET) imaging of the brain. It binds specifically to β-amyloid plaques, allowing visualization and estimation of plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline. The drug crosses the blood-brain barrier after intravenous administration, selectively accumulating in regions with β-amyloid deposits. The positron signal from the fluorine‑18 isotope is detected by PET scanning, providing images that help differentiate Alzheimer's disease from other forms of dementia. Florbetaben does not bind to tau or α-synuclein aggregates and has high plasma protein binding. It was developed for routine clinical use and approved in multiple regions including the US, EU, South Korea, and Canada[1][2][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on florbetaben.